Organon (OGN) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Pfizer (PFE) over the past year, gaining 30.1% versus a gain of 6.6%. Over five years, PFE leads with a -32.5% price change compared with -60.5% for OGN. Pfizer is the larger company by market cap ($159.59 billion vs $3.62 billion), about 44.1 times the size.
On valuation, Organon trades at a lower forward P/E (3.8x vs 9.7x for Pfizer). Pfizer offers the higher dividend yield (6.14% vs 0.58%). Pfizer converts more of its revenue into profit, with a net margin of 12.4% versus 3.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | PFE |
|---|---|---|
| Share price | $13.79 | $28.00 |
| Market cap | $3.62B | $159.59B |
| 1-day change | +0.36% | +1.82% |
| YTD return | +92.33% | +12.45% |
| 1-year return | +30.09% | +6.59% |
| 5-year return | -60.48% | -32.51% |
| P/E ratio (TTM) | 17.68 | 36.36 |
| Forward P/E | 3.81 | 9.67 |
| EPS (TTM) | $0.78 | $0.77 |
| Dividend yield | 0.58% | 6.14% |
| Annual dividend | $0.08 | $1.72 |
| Revenue (latest FY) | $6.22B | $62.58B |
| Revenue growth (YoY) | -2.92% | -1.65% |
| Net income (latest FY) | $187.00M | $7.77B |
| Gross margin | 53.30% | 74.33% |
| Net margin | 3.01% | 12.42% |
| 52-week high | $13.79 | $29.21 |
| 52-week low | $5.69 | $23.62 |
| Distance from 52-week high | 0.00% | -4.14% |
| Analyst consensus | none | buy |
| Avg. price target upside | -18.42% | +3.25% |
| Average volume | 2.65M | 36.02M |
| Shares outstanding | 262.61M | 5.70B |
| Employees | 10,000 | 75,000 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer is about 44.1 times larger than Organon by market value ($159.59B vs $3.62B).
- OGN has outperformed PFE by 23.5 percentage points over the past year.
- Pfizer trades at a higher earnings multiple (36.4x vs 17.7x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.14% vs 0.58%).
- Pfizer is more profitable, keeping 12.4 cents of every revenue dollar as net income versus 3.0 cents for Organon.
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Healthcare · Drug Manufacturers - General · 10,000 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Healthcare · Drug Manufacturers - General · 75,000 employees
OGN vs PFE FAQ
Which is bigger, Organon or Pfizer?
Pfizer (PFE) is larger, with a market capitalization of $159.59B compared with $3.62B for Organon (OGN).
Which stock has performed better over the past year, OGN or PFE?
OGN returned +30.09% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, OGN or PFE?
OGN has the lower trailing P/E at 17.7, versus 36.4 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Organon or Pfizer?
Pfizer has the higher yield at 6.14%, compared with 0.58% for Organon.
Are Organon and Pfizer in the same industry?
Yes. Both are classified in the Drug Manufacturers - General industry within the Healthcare sector.